PX-316 - CAS 253440-95-8

PX-316 is a AKT inhibior. PX-316, when administered intraperitoneally to mice at 150 mg/kg, inhibits Akt activation in HT-29 human tumor xenografts up to 78% at 10 h with recovery to 34% at 48 h. PX-316 has antitumor activity against early human MCF-7 breast cancer and HT-29 colon cancer xenografts in mice. PX-316 formulated in 20% hydroxypropyl-beta-cyclodextrin for intravenous administration is well tolerated in mice and rats with no hemolysis and no hematological toxicity. Thus, PX-316 is the lead compound of a new class of potential agents that inhibit Akt survival signaling.

Others

Others

253337

C28H57O10P

584.72

O(P(OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC)(=O)O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)C[C@H]1O

-20°C

Ice Packs

Small Compound